Welcome to LookChem.com Sign In|Join Free

CAS

  • or

4270-27-3

Post Buying Request

4270-27-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

4270-27-3 Usage

Chemical Properties

White to off-white powder

Uses

Different sources of media describe the Uses of 4270-27-3 differently. You can refer to the following data:
1. 6-Chlorouracil acts as an inhibitor of yeast alcohol dehydrogenase (ADH-H). 6-Chlorouracil is a potential inhibitor of DNA repair glycosylases.
2. Chlorouracil (4-Chlorouracil; 6-Chlorouracil) is a halogenated uracil that is useful in studies of the effects of halogenation on nucleic acid base-pair stability and alkali metal ion affinity. Reaction of 6-chlorouracil with 4-(dimethylamino)pyridine, 4-methylpyridine, and pyridin-4-yl-morpholine yielded pyridinium-substituted uracils as chlorides which were converted into pyridinium uracilates by deprotonation. These heterocyclic mesomeric betaines are cross-conjugated and thus possess separate cationic (pyridinium) and anionic (uracilate) moieties. Calculations and X-ray single crystal analyses may be used to characterize these systems and to compare the salts with the betaines.

Check Digit Verification of cas no

The CAS Registry Mumber 4270-27-3 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 4,2,7 and 0 respectively; the second part has 2 digits, 2 and 7 respectively.
Calculate Digit Verification of CAS Registry Number 4270-27:
(6*4)+(5*2)+(4*7)+(3*0)+(2*2)+(1*7)=73
73 % 10 = 3
So 4270-27-3 is a valid CAS Registry Number.
InChI:InChI=1/C9H7BrN2/c10-9-3-1-2-7(4-9)8-5-11-12-6-8/h1-6H,(H,11,12)

4270-27-3 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • TCI America

  • (C2093)  6-Chlorouracil  >98.0%(T)

  • 4270-27-3

  • 5g

  • 690.00CNY

  • Detail
  • TCI America

  • (C2093)  6-Chlorouracil  >98.0%(T)

  • 4270-27-3

  • 25g

  • 1,990.00CNY

  • Detail
  • Alfa Aesar

  • (L01875)  6-Chlorouracil, 98+%   

  • 4270-27-3

  • 1g

  • 503.0CNY

  • Detail
  • Alfa Aesar

  • (L01875)  6-Chlorouracil, 98+%   

  • 4270-27-3

  • 5g

  • 1682.0CNY

  • Detail

4270-27-3SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 11, 2017

Revision Date: Aug 11, 2017

1.Identification

1.1 GHS Product identifier

Product name 6-Chlorouracil

1.2 Other means of identification

Product number -
Other names 6-chloropyrimidine-2,4-dione

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:4270-27-3 SDS

4270-27-3Synthetic route

2,4,6-trichloropyrimidine
3764-01-0

2,4,6-trichloropyrimidine

6-chlorouracil
4270-27-3

6-chlorouracil

Conditions
ConditionsYield
With sodium hydroxide In water for 3.5h; Reflux;98%
With sodium hydroxide In water for 2h; Reflux;98%
Stage #1: 2,4,6-trichloropyrimidine With sodium hydroxide In water for 1h; Reflux;
Stage #2: With hydrogenchloride In water pH=2 - 3;
97%
6-chloro-2,4-dihydroxypyrimidine
4270-27-3

6-chloro-2,4-dihydroxypyrimidine

6-chlorouracil
4270-27-3

6-chlorouracil

Conditions
ConditionsYield
With sodium hydroxide Reflux; Schlenk technique; Inert atmosphere;92%
6-chloro-2,4-dimethoxypyrimidine
6320-15-6

6-chloro-2,4-dimethoxypyrimidine

6-chlorouracil
4270-27-3

6-chlorouracil

Conditions
ConditionsYield
43%
With hydrogen bromide
With hydrogenchloride
6-hydroxyuracil
67-52-7

6-hydroxyuracil

6-chlorouracil
4270-27-3

6-chlorouracil

Conditions
ConditionsYield
With trichlorophosphate In acetonitrile at 120℃; for 0.166667h; Microwave irradiation;
6-chlorouracil
4270-27-3

6-chlorouracil

diaminodecane
646-25-3

diaminodecane

C18H28N6O4
87624-99-5

C18H28N6O4

Conditions
ConditionsYield
In butan-1-ol for 8h; Heating;100%
6-chlorouracil
4270-27-3

6-chlorouracil

3-chloro-aniline
108-42-9

3-chloro-aniline

6-(3-chlorophenylamino)pyrimidine-2,4(1H,3H)-dione
7269-03-6

6-(3-chlorophenylamino)pyrimidine-2,4(1H,3H)-dione

Conditions
ConditionsYield
at 170℃; for 0.333333h;99%
for 2h; Reflux;95%
In melt at 180 - 200℃;
6-chlorouracil
4270-27-3

6-chlorouracil

chloromethyl methyl ether
107-30-2

chloromethyl methyl ether

1-methoxymethyl-6-chlorouracil
228396-40-5

1-methoxymethyl-6-chlorouracil

Conditions
ConditionsYield
With lithium hydride In N,N-dimethyl-formamide at 0℃; for 0.5h;98.8%
Stage #1: 6-chlorouracil With 1,8-diazabicyclo[5.4.0]undec-7-ene In dichloromethane at 20℃; for 0.166667h;
Stage #2: chloromethyl methyl ether at 0℃; for 0.333333h;
90%
1-methyl-1H-imidazole
616-47-7

1-methyl-1H-imidazole

6-chlorouracil
4270-27-3

6-chlorouracil

3-(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-1-methyl-1H-imidazolium chloride

3-(2,6-dioxo-1,2,3,6-tetrahydropyrimidin-4-yl)-1-methyl-1H-imidazolium chloride

Conditions
ConditionsYield
In chlorobenzene for 8h; Reflux;98%
In chlorobenzene for 7h; Substitution; Heating;59%
6-chlorouracil
4270-27-3

6-chlorouracil

sodium thiophenolate
930-69-8

sodium thiophenolate

6-(phenylthio)pyrimidine-2,4(1H,3H)-dione
15422-05-6

6-(phenylthio)pyrimidine-2,4(1H,3H)-dione

Conditions
ConditionsYield
In N,N,N,N,N,N-hexamethylphosphoric triamide at 90℃; for 0.05h; microwave irradiation;98%
6-chlorouracil
4270-27-3

6-chlorouracil

aniline
62-53-3

aniline

6-anilinouracil
7269-15-0

6-anilinouracil

Conditions
ConditionsYield
at 150℃; for 1h; Inert atmosphere;98%
at 160℃; for 0.333333h; microwave irradiation;95%
at 180℃; for 0.5h;91%
6-chlorouracil
4270-27-3

6-chlorouracil

6-iodo-2,4-dioxopyrimidine
4269-94-7

6-iodo-2,4-dioxopyrimidine

Conditions
ConditionsYield
With hydrogen iodide; sodium iodide at 20℃; for 24h;98%
With sodium iodide In N,N-dimethyl-formamide for 1.5h; Heating / reflux;
With potassium iodide In N,N-dimethyl-formamide for 1.5h; Heating / reflux;
6-chlorouracil
4270-27-3

6-chlorouracil

N,N'-diethyl-N-(3-methyluracil-6-yl)-p-phenylenediamine
337917-66-5

N,N'-diethyl-N-(3-methyluracil-6-yl)-p-phenylenediamine

N,N'-diethyl-N-(3-methyluracil-6-yl)-N'-(uracil-6-yl)-p-phenylenediamine
337917-67-6

N,N'-diethyl-N-(3-methyluracil-6-yl)-N'-(uracil-6-yl)-p-phenylenediamine

Conditions
ConditionsYield
With N,N-diethylaniline at 180℃; for 1h;96%
piperidine
110-89-4

piperidine

6-chlorouracil
4270-27-3

6-chlorouracil

6-piperidyluracil
73823-06-0

6-piperidyluracil

Conditions
ConditionsYield
at 100℃; for 0.25h; microwave irradiation;96%
6-chlorouracil
4270-27-3

6-chlorouracil

4-octyloxyaniline
39905-45-8

4-octyloxyaniline

6-(4-octyloxy-phenylamino)-1H-pyrimidine-2,4-dione

6-(4-octyloxy-phenylamino)-1H-pyrimidine-2,4-dione

Conditions
ConditionsYield
at 200℃; for 3h;95%
6-chlorouracil
4270-27-3

6-chlorouracil

4-(n-hexyloxy)aniline
39905-57-2

4-(n-hexyloxy)aniline

6-(4-hexyloxy-phenylamino)-1H-pyrimidine-2,4-dione

6-(4-hexyloxy-phenylamino)-1H-pyrimidine-2,4-dione

Conditions
ConditionsYield
at 200℃; for 3h;95%
6-chlorouracil
4270-27-3

6-chlorouracil

N-(8-phenylnaphthalene-1-yl)acetamide

N-(8-phenylnaphthalene-1-yl)acetamide

6-[(8-phenylnaphthalen-1-yl)amino]uracil

6-[(8-phenylnaphthalen-1-yl)amino]uracil

Conditions
ConditionsYield
at 180℃; for 0.666667h; Inert atmosphere;95%
6-chlorouracil
4270-27-3

6-chlorouracil

diphenyl diselenide
1666-13-3

diphenyl diselenide

6-chloro-5-(phenylselanyl)pyrimidine-2,4(1H,3H)-dione

6-chloro-5-(phenylselanyl)pyrimidine-2,4(1H,3H)-dione

Conditions
ConditionsYield
With dihydrogen peroxide; sodium iodide In dimethyl sulfoxide at 50℃; for 3h; Schlenk technique;95%
With potassium iodide In dimethyl sulfoxide at 20℃; for 15h; Electrolysis; Green chemistry;90%
With dihydrogen peroxide; sodium iodide In dimethyl sulfoxide at 50℃;87%
With ammonium iodide In N,N-dimethyl-formamide at 50℃; for 2h; Electrochemical reaction; Green chemistry;80%
6-chlorouracil
4270-27-3

6-chlorouracil

4-methoxy-aniline
104-94-9

4-methoxy-aniline

6-(4-methoxyphenylamino)pyrimidine-2,4(1H,3H)-dione
72255-57-3

6-(4-methoxyphenylamino)pyrimidine-2,4(1H,3H)-dione

Conditions
ConditionsYield
In diethylene glycol dimethyl ether Heating;94%
for 2h; Reflux;90%
at 180 - 200℃; for 0.166667 - 0.25h;
In propan-1-ol at 150℃; Microwave irradiation;
6-chlorouracil
4270-27-3

6-chlorouracil

methylhydrazine
60-34-4

methylhydrazine

6-(1-methylhydrazino)uracil
68558-26-9

6-(1-methylhydrazino)uracil

Conditions
ConditionsYield
In ethanol for 2h; Heating;94%
In ethanol at 100℃; for 0.166667h; Microwave irradiation; regioselective reaction;
In ethanol at 100℃; for 0.166667h; Microwave irradiation;
6-chlorouracil
4270-27-3

6-chlorouracil

m-ethylaniline
587-02-0

m-ethylaniline

6-(3-Ethyl-phenylamino)-1H-pyrimidine-2,4-dione
72255-48-2

6-(3-Ethyl-phenylamino)-1H-pyrimidine-2,4-dione

Conditions
ConditionsYield
In diethylene glycol dimethyl ether Heating;94%
6-chlorouracil
4270-27-3

6-chlorouracil

benzylamine
100-46-9

benzylamine

6-benzylaminouracil
5759-80-8

6-benzylaminouracil

Conditions
ConditionsYield
at 130℃; for 0.25h; microwave irradiation;94%
In butan-1-ol for 9h; Heating;90%
Heating;
6-chlorouracil
4270-27-3

6-chlorouracil

N-(6'-hydroxyhexyl)-3,4-dimethylaniline
189748-84-3

N-(6'-hydroxyhexyl)-3,4-dimethylaniline

6-[N-(6'-hydroxyhexyl)-3,4-xylidino]uracil
189748-85-4

6-[N-(6'-hydroxyhexyl)-3,4-xylidino]uracil

Conditions
ConditionsYield
In 1,4-dioxane; water for 15h; Reflux;94%
In 1,4-dioxane; water for 15h; Heating;63%
In 1,4-dioxane; water for 15h; Inert atmosphere; Reflux;
morpholine
110-91-8

morpholine

6-chlorouracil
4270-27-3

6-chlorouracil

6-morpholin-4-yl-1H-pyrimidine-2,4-dione
15783-46-7

6-morpholin-4-yl-1H-pyrimidine-2,4-dione

Conditions
ConditionsYield
at 100℃; for 0.25h; microwave irradiation;94%
6-chlorouracil
4270-27-3

6-chlorouracil

2-(bromomethyl)benzonitrile
22115-41-9

2-(bromomethyl)benzonitrile

2-[(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)methyl]benzonitrile
865758-95-8

2-[(6-chloro-2,4-dioxo-1,2,3,4-tetrahydropyrimidin-1-yl)methyl]benzonitrile

Conditions
ConditionsYield
With sodium hydride; lithium bromide In dimethyl sulfoxide; N,N-dimethyl-formamide at 20℃; for 12h;93.5%
Stage #1: 6-chlorouracil With triethylamine In N,N-dimethyl-formamide at 25℃; for 0.5h;
Stage #2: 2-(bromomethyl)benzonitrile In N,N-dimethyl-formamide at 25℃; for 8h; Reagent/catalyst; Solvent; Temperature;
79.7%
With N-ethyl-N,N-diisopropylamine In N,N-dimethyl-formamide at 20℃;58%
6-chlorouracil
4270-27-3

6-chlorouracil

4-amino-phenol
123-30-8

4-amino-phenol

6-((4-hydroxyphenyl)amino)pyrimidine-2,4(1H,3H)-dione
72255-56-2

6-((4-hydroxyphenyl)amino)pyrimidine-2,4(1H,3H)-dione

Conditions
ConditionsYield
In diethylene glycol dimethyl ether Heating;93%
In ethanol at 150℃; for 0.5h; Microwave irradiation;75%
In propan-1-ol at 150℃; Microwave irradiation;
In ethanol at 150℃; for 0.5h; Microwave irradiation;
6-chlorouracil
4270-27-3

6-chlorouracil

para-thiocresol
106-45-6

para-thiocresol

6-chloro-5-(p-tolylthio)pyrimidine-2,4(1H,3H)-dione

6-chloro-5-(p-tolylthio)pyrimidine-2,4(1H,3H)-dione

Conditions
ConditionsYield
With dihydrogen peroxide; sodium iodide In dimethyl sulfoxide at 100℃; for 18h; Schlenk technique;93%
With dihydrogen peroxide; sodium iodide In dimethyl sulfoxide at 100℃; for 15h;83%
6-chlorouracil
4270-27-3

6-chlorouracil

1-deoxy-1-[(2,6-dioxo-1,2,3,6-tetrahydro-4-pyrimidinyl)amino]-D-ribitol
33106-48-8

1-deoxy-1-[(2,6-dioxo-1,2,3,6-tetrahydro-4-pyrimidinyl)amino]-D-ribitol

Conditions
ConditionsYield
With triethylamine In ethylene glycol at 170℃; for 0.5h;92%
for 12h; Heating;60%
With potassium hydroxide at 20℃; for 0.5h;16%
at 128℃;
6-chlorouracil
4270-27-3

6-chlorouracil

thiophenol
108-98-5

thiophenol

6-(phenylthio)pyrimidine-2,4(1H,3H)-dione
15422-05-6

6-(phenylthio)pyrimidine-2,4(1H,3H)-dione

Conditions
ConditionsYield
In pyridine for 1h; Heating;92%
With potassium carbonate In ethylene glycol Substitution;
With pyridine for 1.5h; Heating;
With pyridine Heating;
6-chlorouracil
4270-27-3

6-chlorouracil

benzyl-methyl-amine
103-67-3

benzyl-methyl-amine

6-(benzylmethylamino)uracil
21333-17-5

6-(benzylmethylamino)uracil

Conditions
ConditionsYield
at 130℃; for 0.333333h; microwave irradiation;92%
6-chlorouracil
4270-27-3

6-chlorouracil

N-ethyl-N-phenylamine
103-69-5

N-ethyl-N-phenylamine

6-(ethyl(phenyl)amino)pyrimidine-2,4(1H,3H)-dione
27281-43-2

6-(ethyl(phenyl)amino)pyrimidine-2,4(1H,3H)-dione

Conditions
ConditionsYield
at 175℃; for 0.333333h;92%
6-chlorouracil
4270-27-3

6-chlorouracil

1-aminooctadecane
124-30-1

1-aminooctadecane

6-Octadecylaminouracil
127984-96-7

6-Octadecylaminouracil

Conditions
ConditionsYield
In butan-1-ol for 5h; Heating;91%
6-chlorouracil
4270-27-3

6-chlorouracil

N-ethyl-p-tolylamine
622-57-1

N-ethyl-p-tolylamine

6-(N-ethyl-p-toluidino)uracil
77778-47-3

6-(N-ethyl-p-toluidino)uracil

Conditions
ConditionsYield
91%

4270-27-3Relevant articles and documents

Invariant and Variable Supramolecular Self-Assembly in 6-Substituted Uracil Derivatives: Insights from X-ray Structures and Quantum Chemical Study

Abdelbaky, Mohammed S. M.,Al-Wahaibi, Lamya H.,Bysani, Sai Ramya Sree,El-Emam, Ali A.,Garcia-Granda, Santiago,Percino, M. Judith,Tawfik, Samar S.,Thamotharan, Subbiah

, p. 3234 - 3250 (2021/05/29)

In this study, three new 6-(arylthio)uracil derivatives, namely, 6-(phenylthio)pyrimidine-2,4(1H,3H)-dione (1), C10H8N2O2S; 6-(p-tolylthio)pyrimidine-2,4(1H,3H)-dione (2), C11H10N2O2S; and 6-(3,5-dimethylphenylthio)pyrimidine-2,4(1H,3H)-dione (3), C12H12N2O2S, have been synthesized. Single-crystal structures of these compounds reveal an invariant molecular tape contains alternate R22(8) synthons formed by N-H···O hydrogen bonds in 1 and 3. This alternate hydrogen-bonded pattern disappeared in 2; instead, a new synthon is generated. The lattice energy calculation suggests that the methyl-substituted derivatives (2 and 3) have high stabilization energy than compound 1. The electrostatic potential map reveals the difference in the accepting tendency of the carbonyl oxygen. The Hirshfeld surface and 2D-fingerprint plots analyses demonstrate that the major intermolecular interactions come from H···O contacts in 1, and these contacts were reduced due to the presence of methyl substitutions in 2 and 3. This reduction is compensated by the increase of the same amount of H···H contacts in these structures. Further, the PIXEL energy and DFT calculations at the M06-2X-D3/cc-pVTZ level of theory were used to characterize the dimeric topology formed in structures of 1-3. The intermolecular interaction energies of dimers calculated by the PIXEL method were compared with the B97D3/def2-TZVP level of approximation. Although these molecules' crystal packing is somewhat different, the energy frameworks show similarities on the respective crystal structure's shortest axis. Furthermore, the nature and strength of various noncovalent interactions such as N-H···O, C-H···O/S/π, π···π, and a chalcogen bond of type C-S···O═C were evaluated using the Bader's quantum theory of atoms-in-molecules framework.

Toxoflavins and deazaflavins as the first reported selective small molecule inhibitors of tyrosyl-DNA phosphodiesterase II

Raoof, Ali,Depledge, Paul,Hamilton, Niall M.,Hamilton, Nicola S.,Hitchin, James R.,Hopkins, Gemma V.,Jordan, Allan M.,Maguire, Laura A.,McGonagle, Alison E.,Mould, Daniel P.,Rushbrooke, Mathew,Small, Helen F.,Smith, Kate M.,Thomson, Graeme J.,Turlais, Fabrice,Waddell, Ian D.,Waszkowycz, Bohdan,Watson, Amanda J.,Ogilvie, Donald J.

, p. 6352 - 6370 (2013/09/23)

The recently discovered enzyme tyrosyl-DNA phosphodiesterase 2 (TDP2) has been implicated in the topoisomerase-mediated repair of DNA damage. In the clinical setting, it has been hypothesized that TDP2 may mediate drug resistance to topoisomerase II (topo II) inhibition by etoposide. Therefore, selective pharmacological inhibition of TDP2 is proposed as a novel approach to overcome intrinsic or acquired resistance to topo II-targeted drug therapy. Following a high-throughput screening (HTS) campaign, toxoflavins and deazaflavins were identified as the first reported sub-micromolar and selective inhibitors of this enzyme. Toxoflavin derivatives appeared to exhibit a clear structure-activity relationship (SAR) for TDP2 enzymatic inhibition. However, we observed a key redox liability of this series, and this, alongside early in vitro drug metabolism and pharmacokinetics (DMPK) issues, precluded further exploration. The deazaflavins were developed from a singleton HTS hit. This series showed distinct SAR and did not display redox activity; however low cell permeability proved to be a challenge.

Synthesis and biological evaluation of novel pyrimido[4,5-b]quinoline-2,4- dione derivatives as MDM2 ubiquitin ligase inhibitors

Dou, Xiaoxue,Li, Xin,Tao, Liu,Hu, Chunqi,Zhang, Lei,He, Qiaojun,Yang, Bo,Hu, Yongzhou

, p. 581 - 587 (2013/07/28)

A series of pyrimido[4,5-b]quinoline-2,4-dione derivatives was synthesized and evaluated for their cytotoxic activities in vitro against five human cancer cell lines. Selected compounds were tested for their MDM2 E3 ligase inhibitory activities and p53-MDM2 binding inhibitory activities. Among tested compounds, four sulfur-containing compounds (4-7) displayed enhanced cytotoxic activities and better MDM2 E3 ligase inhibitoty activities in comparison with that of HLI98c. Three compounds (4-6) showed better p53-MDM2 binding inhibitory potency with IC50 values ranging from 1.3 μM to 9.0 μM.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 4270-27-3